Patents by Inventor Isabelle Catelas

Isabelle Catelas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOMATERIALS FOR BONE TISSUE ENGINEERING
    Publication number: 20220395611
    Abstract: Provided herein are scaffold biomaterials including a decellularized plant or fungal tissue from which cellular materials and nucleic acids of the tissue are removed, the decellularized plant or fungal tissue having a 3-dimensional porous structure; wherein the decellularized plant or fungal tissue may optionally be at least partially coated or mineralized, wherein the scaffold biomaterial may optionally further include a protein-based hydrogel and/or a polysaccharide-based hydrogel, or both. Also provided herein are methods and uses of such scaffold biomaterials, including methods of manufacture as well as methods and uses for bone tissue engineering, for example.
    Type: Application
    Filed: December 18, 2020
    Publication date: December 15, 2022
    Inventors: Maxime LEBLANC LATOUR, Ryan HICKEY, Charles M. CUERRIER, Andrew E. PELLING, Maryam TARAR, Isabelle CATELAS
  • Fibrin gel for controlled release of PDGF and uses thereof
    Patent number: 9012393
    Abstract: The present invention relates, in general, to fibrin sealants, which contain platelet derived growth factor (PDGF) for controlled release in situ for therapeutic applications, including musculoskeletal disorders, soft tissue disorders and vascular diseases.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: April 21, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Isabelle Catelas, Joseph Dwyer, Wanda Seyton, Shane Donovan, Sam L. Helgerson
  • Fibrin gel for controlled release of PDGF and uses thereof
    Patent number: 8377864
    Abstract: The present invention relates, in general, to fibrin sealants, which contain platelet derived growth factor (PDGF) for controlled release in situ for therapeutic applications, including musculoskeletal disorders, soft tissue disorders and vascular diseases.
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: February 19, 2013
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Isabelle Catelas, Joseph Dwyer, Wanda Seyton, Shane Donovan, Sam L. Helgerson
  • FIBRIN GEL FOR CONTROLLED RELEASE OF PDGF AND USES THEREOF
    Publication number: 20090075881
    Abstract: The present invention relates, in general, to fibrin sealants, which contain platelet derived growth factor (PDGF) for controlled release in situ for therapeutic applications, including musculoskeletal disorders, soft tissue disorders and vascular diseases.
    Type: Application
    Filed: June 19, 2008
    Publication date: March 19, 2009
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Isabelle Catelas, Joseph Dwyer, Wanda Seyton, Shane Donovan, Sam L. Helgerson
  • FIBRIN GEL FOR CONTROLLED RELEASE OF TGF-BETA AND USES THEREOF
    Publication number: 20080181879
    Abstract: The present invention relates, in general, to fibrin sealants, which contain transforming growth factor-beta (TGF-?) for controlled release in situ for therapeutic applications, including musculoskeletal disorders, such as bone and cartilage disorders, soft tissue disorders and cardiovascular diseases.
    Type: Application
    Filed: January 18, 2008
    Publication date: July 31, 2008
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Isabelle Catelas, Sam L. Helgerson